Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 7/2016

Open Access 01-07-2016 | Original Article

DACH1 inhibits the proliferation and invasion of lung adenocarcinoma through the downregulation of peroxiredoxin 3

Authors: Ji Zhu, Cong Wu, Huafei Li, Yang Yuan, Xiaotian Wang, Tiejun Zhao, Jibin Xu

Published in: Tumor Biology | Issue 7/2016

Login to get access

Abstract

In this study, we found the expression of Dachshund 1 (DACH1) is downregulated while peroxiredoxin 3 (PRX3) upregulated in both lung adenocarcinoma tissues and cells. Transfection of DACH1 can significantly downregulate PRX3 expression in targeting lung adenocarcinoma cells. Further experimental results demonstrated the evidence that overexpression of DACH1 resulted in significant retardation of in vitro proliferation and invasion of lung adenocarcinoma cells. Direct upregulation of PRX3 by co-transfection of PRX3 messenger RNA (mRNA) can prevent the above alteration caused by DACH1 transfection. Besides, lower DACH1 expression significantly correlated with tumor diameter and tumor invasion in all the 36 patients diagnosed with lung adenocarcinoma in our hospital during the past months. In conclusion, DACH1 can inhibit the proliferation and invasion of lung adenocarcinoma through the downregulation of PRX3. Decreased expression of DACH1 is involved in the initiation and development of lung cancer, which might be an adverse prognostic factor of lung adenocarcinoma.
Appendix
Available only for authorised users
Literature
1.
Ridge CA, McErlean AM, Ginsberg MS. Epidemiology of lung cancer. Semin Interv Radiol. 2013;30:93–8.CrossRef
2.
Rivera MP. Lung cancer in women: differences in epidemiology, biology, histology, and treatment outcomes. Semin Respir Crit Care Med. 2013;34:792–801.CrossRefPubMed
3.
4.
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015.
5.
Walsh K, Wallace WA. Molecular pathology in lung cancer: a guide to the techniques used in clinical practice. Histopathology. 2014;65:731–41.CrossRefPubMed
6.
Zhan P, Qian Q, Yu LK. Prognostic value of COX-2 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis. J Thorac Dis. 2013;5:40–7.PubMedPubMedCentral
7.
Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497–500.CrossRefPubMed
8.
Qi WX, Shen Z, Lin F, Sun YJ, Min DL, Tang LN, et al. Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2012;13:5177–82.CrossRefPubMed
9.
Kobayashi K, Hagiwara K. Epidermal growth factor receptor (EGFR) mutation and personalized therapy in advanced nonsmall cell lung cancer (NSCLC). Target Oncol. 2013;8:27–33.CrossRefPubMedPubMedCentral
10.
Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. 2006;12:6494–501.CrossRefPubMed
11.
Zhou J, Wang C, Wang Z, Dampier W, Wu K, Casimiro MC, et al. Attenuation of Forkhead signaling by the retinal determination factor DACH1. Proc Natl Acad Sci U S A. 2010;107:6864–9.CrossRefPubMedPubMedCentral
12.
Chen K, Wu K, Cai S, Zhang W, Zhou J, Wang J, et al. Dachshund binds p53 to block the growth of lung adenocarcinoma cells. Cancer Res. 2013;73:3262–74.CrossRefPubMedPubMedCentral
13.
Wu K, Katiyar S, Witkiewicz A, Li A, McCue P, Song LN, et al. The cell fate determination factor dachshund inhibits androgen receptor signaling and prostate cancer cellular growth. Cancer Res. 2009;69:3347–55.CrossRefPubMedPubMedCentral
14.
Wu K, Li A, Rao M, Liu M, Dailey V, Yang Y, et al. DACH1 is a cell fate determination factor that inhibits cyclin D1 and breast tumor growth. Mol Cell Biol. 2006;26:7116–29.CrossRefPubMedPubMedCentral
15.
Wu K, Jiao X, Li Z, Katiyar S, Casimiro MC, Yang W, et al. Cell fate determination factor Dachshund reprograms breast cancer stem cell function. J Biol Chem. 2011;286:2132–42.CrossRefPubMed
16.
Yamada Y, Arao T, Gotoda T, Taniguchi H, Oda I, Shirao K, et al. Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples. Cancer Sci. 2008;99:2193–9.CrossRefPubMed
17.
Han N, Yuan X, Wu H, Xu H, Chu Q, Guo M, et al. DACH1 inhibits lung adenocarcinoma invasion and tumor growth by repressing CXCL5 signaling. Oncotarget. 2015;6:5877–88.CrossRefPubMedPubMedCentral
18.
Toledano MB, Delaunay-Moisan A. Keeping oxidative metabolism on time: mitochondria as an autonomous redox pacemaker animated by H2O2 and peroxiredoxin. Mol Cell. 2015;59:517–9.CrossRefPubMed
19.
Shuvaeva TM, Novoselov VI, Fesenko EE, Lipkin VM. Peroxiredoxins, a new family of antioxidant proteins. Bioorg Khim. 2009;35:581–96.PubMed
20.
Rhee SG, Woo HA, Kil IS, Bae SH. Peroxiredoxin functions as a peroxidase and a regulator and sensor of local peroxides. J Biol Chem. 2012;287:4403–10.CrossRefPubMed
21.
Hu JX, Gao Q, Li L. Peroxiredoxin 3 is a novel marker for cell proliferation in cervical cancer. Biomed Rep. 2013;1:228–30.PubMed
22.
Nonn L, Berggren M, Powis G. Increased expression of mitochondrial peroxiredoxin-3 (thioredoxin peroxidase-2) protects cancer cells against hypoxia and drug-induced hydrogen peroxide-dependent apoptosis. Mol Cancer Res. 2003;1:682–9.PubMed
23.
Kalinina EV, Berezov TT, Shtil' AA, Chernov NN, Glazunova VA, Novichkova MD, et al. Expression of peroxiredoxin 1, 2, 3, and 6 genes in cancer cells during drug resistance formation. Bull Exp Biol Med. 2012;153:878–81.CrossRefPubMed
24.
Silvestri GA, Gonzalez AV, Jantz MA, Margolis ML, Gould MK, Tanoue LT, et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143:e211S–50.CrossRefPubMed
25.
Wu C, Xue Y, Wang P, Lin L, Liu Q, Li N, et al. IFN-gamma primes macrophage activation by increasing phosphatase and tensin homolog via downregulation of miR-3473b. J Immunol. 2014;193:3036–44.CrossRefPubMed
26.
Zhang J, Jia J, Zhao L, Li X, Xie Q, Chen X, Wang J, Lu F. Down-regulation of microRNA-9 leads to activation of IL-6/Jak/STAT3 pathway through directly targeting IL-6 in HeLa cell. Mol Carcinog. 2015.
27.
Li H, Guo K, Wu C, Shu L, Guo S, Hou J, Zhao N, Wei L, Man X, Zhang L. Controlled and targeted drug delivery by a UV-responsive liposome for overcoming chemo-resistance in non-Hodgkin lymphoma. Chem Biol Drug Des. 2015.
28.
Lee JW, Kim HS, Kim S, Hwang J, Kim YH, Lim GY, et al. DACH1 regulates cell cycle progression of myeloid cells through the control of cyclin D, Cdk 4/6 and p21Cip1. Biochem Biophys Res Commun. 2012;420:91–5.CrossRefPubMed
29.
Weinberg F, Hamanaka R, Wheaton WW, Weinberg S, Joseph J, Lopez M, et al. Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci U S A. 2010;107:8788–93.CrossRefPubMedPubMedCentral
30.
Park HJ, Carr JR, Wang Z, Nogueira V, Hay N, Tyner AL, et al. FoxM1, a critical regulator of oxidative stress during oncogenesis. EMBO J. 2009;28:2908–18.CrossRefPubMedPubMedCentral
31.
Song IS, Jeong YJ, Jeong SH, Heo HJ, Kim HK, Bae KB, et al. FOXM1-Induced PRX3 regulates stemness and survival of colon cancer cells via maintenance of mitochondrial function. Gastroenterology. 2015;149:1006–16.CrossRefPubMed
Metadata
Title
DACH1 inhibits the proliferation and invasion of lung adenocarcinoma through the downregulation of peroxiredoxin 3
Authors
Ji Zhu
Cong Wu
Huafei Li
Yang Yuan
Xiaotian Wang
Tiejun Zhao
Jibin Xu
Publication date
01-07-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 7/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-4811-x

Other articles of this Issue 7/2016

Tumor Biology 7/2016 Go to the issue

Original Article

MiR-608 rs4919510 is associated with prognosis of hepatocellular carcinoma

Original Article

High expression of constitutive photomorphogenic 1 (COP1) is associated with poor prognosis in bladder cancer

Original Article

MicroRNA-21 promotes proliferation, invasion and suppresses apoptosis in human osteosarcoma line MG63 through PTEN/Akt pathway

Original Article

Hypersplenism is correlated with increased risk of hepatocellular carcinoma in patients with post-hepatitis cirrhosis

Original Article

A novel dual-targeted ultrasound contrast agent provides improvement of gene delivery efficiency in vitro

Original Article

Pre-treatment VD levels and VDR receptors as potential predictors of occurrence and overall survival in paediatric patients with solid tumours—a single institution pilot study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits